Efficacy and Safety of Artesunate-Amodiaquine versus Artemether-Lumefantrine in the Treatment of Uncomplicated Plasmodium falciparum Malaria in Sentinel Sites across Côte d’Ivoire

Table 2

PCR-uncorrected and PCR-adjusted days 14 and 28 treatment outcomes according to study participant ages.

Age (year)	ASAQ (%)				AL (%)
	[2–5[	[5–15[	[15–63]	Total	[2–5[	[5–15[	15–63	Total
PCR-uncorrected day 14 cure rates
ACPR	69/69 (100)	57/57 (100)	17/17 (100)	143/143 (100)	61/62 (98.4)	73/73 (100)	11/11 (100)	145/146 (99.3)
ETF	0/69 (0)	0/57 (0)	0/17 (0)	0/143 (0)	1/62 (1.6)	0/73 (0)	0/11 (0)	1/146 (0.7)
LCF	0/69 (0)	0/57 (0)	0/17 (0)	0/143 (0)	0/62 (0)	0/73 (0)	0/11 (0)	0/146 (0)
PCR-uncorrected day 28 cure rates
ACPR	68/69 (98.5)	57/57 (100)	17/17 (100)	142/143 (99.3)	59/62 (95.2)	68/73 (93.2)	11/11 (100)	138/146 (94.5)
ETF	0/69 (0)	0/57 (0)	0/17 (0)	0/143 (0)	1/62 (1.6)	0/73 (0)	0/11 (0)	1/146 (0.7)
LCF	1/69 (1.4)	0/57 (0)	0/17 (0)	1/143 (0.7)	2/62 (3.2)	5/73 (6.8)	0/11 (0)	7/146 (4.8)
PCR-corrected day 28 cure rates
ACPR	68/69 (98.6)	57/57 (100)	17/17 (100)	142/143 (99.3)	61/62 (98.4)	73/73 (100)	11/11 (100)	145/146 (99.3)
ETF	0/69 (0)	0/57 (0)	0/17 (0)	0/143 (0)	1/62 (1.6)	0/73 (0)	0/11 (0)	1/146 (0.7)
LCF	1/69 (1.4)	0/57 (0)	0/17 (0)	1/143 (0.7)	0/62 (0)	0/73 (0)	0/11 (0)	0/146 (0)